Dr
Poster title: Iron absorption is maintained over time following repeated twice-daily ferric maltol dosing: Post hoc analysis of a multicenter, open-label, randomized, phase 1 clinical study.
Poster Presentation Dates and times:
NPWH is the leading membership organization for Women's Health Nurse Practitioners and all NPs who perform women's and gender-related healthcare. Through continuing education, advocacy, professional development, and research, we support our members as they strive to continuously improve access to and quality of healthcare for women.
About Iron Deficiency and Accrufer/Feraccru
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a
Accrufer/Feraccru (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. Accrufer/Feraccru has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials.
About
Shield is a commercial stage specialty pharmaceutical company that delivers Accrufer/Feraccru (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company launched Accrufer in the
Contact:
Tel: +44 (0) 191 511 8500
Email: info@shieldtx.com
(C) 2023 Electronic News Publishing, source